Alsalemi Wardah, Chik Zamri, Alshawsh Mohammed Abdullah
Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Universiti Malaya Research Centre for Biopharmaceuticals and Advanced Therapeutics (UBAT), Department of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
PLoS One. 2025 Jun 24;20(6):e0324926. doi: 10.1371/journal.pone.0324926. eCollection 2025.
Disruption of the gut microbiota, an essential ecosystem of microorganisms inhabiting the gastrointestinal tract (GIT), has been linked to the development and progression of various gastrointestinal disorders. Probiotics have received considerable attention for their role in gastrointestinal diseases. However, there is a need to synthesise existing evidence to determine the optimal probiotic approach for managing complications of GIT disorders. By conducting a systematic review of randomised controlled trials (RCTs) comparing the effects of probiotic bacteria and yeast in patients with gastrointestinal diseases, we aim to provide a comprehensive and evidence-based analysis of the benefits and limitations of these interventions, which could inform clinical decision-making and improve patient outcomes in this population.
Different databases, including PubMed, Web of Science, and Scopus will be searched to identify randomized controlled trials (RCTs). The titles and abstracts will be screened using Rayyan, and data will be extracted from eligible studies using Microsoft Excel. Critical appraisal and quality assessment will be performed using the ROB 2 tool, while GradePro will be used to assess the certainty of outcomes. All steps will be independently performed by two reviewers. This study will assess the effectiveness of yeast and bacterial probiotics in treating GIT disorders by evaluating inflammation markers, diarrhoeal score and disease severity, stool frequency, length of hospital stay, and adverse effects. By comparing the efficacy of probiotic bacteria and yeast, this review will identify the most effective type of probiotics for different gastrointestinal disorders, potentially enhancing treatment outcomes and reducing healthcare costs. Systematic review registration: PROSPERO (CRD42023384070).
肠道微生物群是栖息于胃肠道（GIT）的重要微生物生态系统，其破坏与各种胃肠道疾病的发生和发展有关。益生菌因其在胃肠道疾病中的作用而受到广泛关注。然而，需要综合现有证据来确定管理GIT疾病并发症的最佳益生菌方法。通过对比较益生菌和酵母对胃肠道疾病患者影响的随机对照试验（RCT）进行系统评价，我们旨在对这些干预措施的益处和局限性进行全面且基于证据的分析，为临床决策提供参考并改善该人群的患者预后。
将检索包括PubMed、Web of Science和Scopus在内的不同数据库，以识别随机对照试验（RCT）。使用Rayyan筛选标题和摘要，并使用Microsoft Excel从符合条件的研究中提取数据。将使用ROB 2工具进行关键评估和质量评估，而GradePro将用于评估结果的确定性。所有步骤将由两名评审员独立执行。本研究将通过评估炎症标志物、腹泻评分和疾病严重程度、大便频率、住院时间和不良反应来评估酵母和细菌益生菌治疗GIT疾病的有效性。通过比较益生菌和酵母的疗效，本综述将确定针对不同胃肠道疾病最有效的益生菌类型，可能提高治疗效果并降低医疗成本。系统评价注册：PROSPERO（CRD42023384070）。
